Serious adverse events · people with acute HBV infection
1 finding from 1 review
All other (non‐serious) adverse events · people with chronic hepatitis C
1 finding from 1 review
Serious adverse events Number of events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
Serious adverse events · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Serious adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).
1 finding from 1 review